Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Bitcoin At Risk Of 50% Drop Before Next Halving If Historical Trend Repeats, Warns Influential Crypto Guru
-
Affirm Shares Ascend Following Deal With Walmart
-
Evoqua Water Technologies Rises On Better-than-expected Results
-
Cryptos Muted As Geopolitics And Interest Rate Worries Bother
-
Jim Cramer Calls $BTC ‘A Strange Animal’, Says ‘I Would Sell My Bitcoin Right Into This Rally’